Background:

This meta-analysis explored the correlation between the C-reactive protein to albumin ratio (CAR) and survival outcomes and clinicopathological characteristics in patients with pancreatic cancer.

Methods:

PubMed, Embase, Web of Science, and Cochrane Library databases were comprehensively searched through October 17, 2019. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were used to evaluate the association between CAR and overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS) in pancreatic cancer.

Results:

The meta-analysis included 11 studies comprising 2271 patients. The pooled results showed that a high CAR was predictive of worse OS (HR = 1.84, 95% CI = 1.65-2.06, P < .001), PFS (HR = 1.53, 95% CI = 1.27-1.85, P < .001), and DFS (HR = 1.77, 95% CI = 1.30-2.41, P < .001). An elevated CAR was also associated with male sex (OR = 1.38, 95% CI = 1.10-1.74, P = .006).

Conclusion:

Elevated pretreatment CAR effectively predicts inferior survival outcomes in patients with pancreatic cancer and may be a powerful prognostic indicator for these patients.

中文翻译：

---

胰腺癌患者 C 反应蛋白与白蛋白比率的预后和临床病理学意义：荟萃分析。

背景：

这项荟萃分析探讨了胰腺癌患者 C 反应蛋白与白蛋白比率 (CAR) 与生存结果和临床病理学特征之间的相关性。

方法：

对 PubMed、Embase、Web of Science 和 Cochrane Library 数据库进行了全面搜索，截至 2019 年 10 月 17 日。汇总风险比 (HR) 和 95% 置信区间 (CI) 用于评估 CAR 与总生存期 (OS) 之间的关联，胰腺癌的无进展生存期（PFS）和无病生存期（DFS）。

结果：

荟萃分析包括 11 项研究，包括 2271 名患者。汇总结果表明，高 CAR 可预测较差的 OS（HR = 1.84，95% CI = 1.65-2.06，P < .001），PFS（HR = 1.53，95% CI = 1.27-1.85，P < .001 ) 和 DFS (HR = 1.77, 95% CI = 1.30-2.41, P < .001)。升高的 CAR 也与男性相关（OR = 1.38, 95% CI = 1.10-1.74, P = .006）。

结论：

升高的预处理 CAR 可有效预测胰腺癌患者的较差生存结果，并且可能是这些患者的有力预后指标。